Progress in research on perimenopausal depression
10.3760/cma.j.cn101441-20190928-00438
- VernacularTitle:围绝经期抑郁的研究新进展
- Author:
Jing SHUI
1
;
Ketan CHU
1
;
Linjuan MA
1
;
Jianhong ZHOU
1
Author Information
1. 浙江大学医学院附属妇产科医院妇科 310006
- Publication Type:Journal Article
- Keywords:
Perimenopause;
Depression;
Estrogen
- From:
Chinese Journal of Reproduction and Contraception
2020;40(10):842-846
- CountryChina
- Language:Chinese
-
Abstract:
The cause of perimenopausal depression is not clear, decrease in ovarian function and increase in hormonal fluctuations are considered to be the main causes. With the aging of the population, the incidence of perimenopausal depression increased significantly, which seriously impacts the physical and mental health of women. Screening of depression in perimenopausal women should be conducted to recognize depression in the early stage. In 2018, the North American Menopause Society (NAMS) and the National Network of Depression Centers Women and Mood Disorders Task Group (NNDC) have developed the guideline for the assessment and treatment of perimenopausal depression, which defined the diagnostic criteria for perimenopausal depression. Antidepressants is considered as first-line treatment for perimenopausal depression. However, studies have confirmed that estrogen has antidepressant effects, but there are still different opinions on the application of hormone therapy. This article reviewed this guideline and the latest literatures of the screening, diagnosis and treatment of perimenopausal depression.
